Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
Omid Hamid(Cedars-Sinai Medical Center), Marc S. Ernstoff(National Cancer Institute), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Heather C. Losey(Alkermes (United States)), Bradley Curtis Carthon(Emory University), Stephen V. Liu(Georgetown University), Justin Call, Trisha M. Wise‐Draper(University of Cincinnati), Craig Hopkinson(Alkermes (United States)), Anthony F. Shields(Wayne State University), Ulka N. Vaishampayan(University of Michigan), Lei Sun(Alkermes (United States)), Anthony J. Olszanski(Fox Chase Cancer Center), John Wrangle(Johns Hopkins University), John D. Powderly(Carolina BioOncology Institute), Yan Wang(Second Affiliated Hospital of Jilin University), Yangchun Du(Boston University), Monali Desai(AbbVie (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Angela Alistar
Cited by 12
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k